CAR T cell therapy for treatment of lupus Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0 Note - cytokine release syndrome in 3 pts. Excellent overview of CAR T cell therapy and its complexity! @RheumNow #ACR22 https://t.co/3PP14tVudb

#acr22 The Rise of JAK in rheumatology Look for Ab1117 in plenary 2 tomorrow for DEU and SLE @RheumNow https://t.co/nLpXGyrhfJ

#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj

• Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results …

#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY

• Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in…

#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav

• Implementability of a SLE Medication Adherence Intervention - ACR Meeting Abstr…

#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD